Found: 19
Select item for more details and to access through your institution.
Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-021-27833-0
- By:
- Publication type:
- Article
Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses.
- Published in:
- Clinical & Experimental Medicine, 2023, v. 23, n. 8, p. 5445, doi. 10.1007/s10238-023-01227-6
- By:
- Publication type:
- Article
Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-021-27833-0
- By:
- Publication type:
- Article
Evaluation of the PIK3 pathway in peripheral T‐cell lymphoma and NK/T‐cell lymphoma.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 4, p. 731, doi. 10.1111/bjh.16435
- By:
- Publication type:
- Article
The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.
- Published in:
- Experimental Dermatology, 2014, v. 23, n. 8, p. 579, doi. 10.1111/exd.12470
- By:
- Publication type:
- Article
Doxorubicin-induced activation of NF-κB in melanoma cells is abrogated by inhibition of IKKβ, but not by a novel IKKα inhibitor.
- Published in:
- Experimental Dermatology, 2012, v. 21, n. 4, p. 301, doi. 10.1111/j.1600-0625.2012.01440.x
- By:
- Publication type:
- Article
Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer.
- Published in:
- Journal of Translational Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12967-024-05453-8
- By:
- Publication type:
- Article
A new model of cell cycle-regulated transcription: repression of the cyclin A promoter by CDF-1 and anti-repression by E2F.
- Published in:
- Oncogene, 1998, v. 16, n. 23, p. 2957, doi. 10.1038/sj.onc.1201838
- By:
- Publication type:
- Article
The Differential Binding of E2F and CDF Repressor Complexes Contributes to the Timing of Cell Cycle-Regulated Transcription.
- Published in:
- Nucleic Acids Research, 1997, v. 25, n. 24, p. 4921, doi. 10.1093/nar/25.24.4921
- By:
- Publication type:
- Article
CDF-1, a Novel E2F-Unrelated Factor, Interacts With Cell Cycle-Regulated Repressor Elements in Multiple Promoters.
- Published in:
- Nucleic Acids Research, 1997, v. 25, n. 24, p. 4915, doi. 10.1093/nar/25.24.4915
- By:
- Publication type:
- Article
Cell Cycle-Regulated Repression of B-myb Transcription: Cooperation of an E2F Site with a Contiguous Corepressor Element.
- Published in:
- Nucleic Acids Research, 1996, v. 24, n. 3, p. 2905, doi. 10.1093/nar/24.15.2905
- By:
- Publication type:
- Article
Response to 'The role of T-bet in B cells'.
- Published in:
- 2003
- By:
- Publication type:
- Letter
CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells.
- Published in:
- Nature Immunology, 2003, v. 4, n. 7, p. 687, doi. 10.1038/ni941
- By:
- Publication type:
- Article
RETRACTED ARTICLE: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.
- Published in:
- Nature Communications, 2017, v. 8, n. 1, p. 1, doi. 10.1038/ncomms14687
- By:
- Publication type:
- Article
TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.
- Published in:
- Nature Communications, 2017, v. 8, n. 3, p. 14687, doi. 10.1038/ncomms14687
- By:
- Publication type:
- Article
BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
- Published in:
- International Journal of Cancer, 2017, v. 140, n. 2, p. 449, doi. 10.1002/ijc.30457
- By:
- Publication type:
- Article
Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
- Published in:
- International Journal of Cancer, 2015, v. 137, n. 9, p. 2234, doi. 10.1002/ijc.29579
- By:
- Publication type:
- Article
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2- c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946).
- Published in:
- ChemMedChem, 2016, v. 11, n. 14, p. 1517, doi. 10.1002/cmdc.201600148
- By:
- Publication type:
- Article